{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:31:35Z","timestamp":1740119495792,"version":"3.37.3"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-007625"],"award-info":[{"award-number":["INV-007625"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejps.2024.106781","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T01:36:28Z","timestamp":1714700188000},"page":"106781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Integrated models of population pharmacokinetics and exposure response to optimize dosage regimen for anaprazole sodium in duodenal ulcer"],"prefix":"10.1016","volume":"198","author":[{"given":"Lei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueting","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2022","series-title":"Population Pharmacokinetics Guidance for Industry","key":"10.1016\/j.ejps.2024.106781_bib0001"},{"key":"10.1016\/j.ejps.2024.106781_bib0002","first-page":"484","article-title":"Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19","volume":"70","author":"Furuta","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106781_bib0003","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00228-012-1252-3","article-title":"CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers","volume":"68","author":"Gawro\u0144ska-Szklarz","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106781_bib0004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/DHPS.S133286","article-title":"Evaluating cardiac risk: exposure response analysis in early clinical drug development","volume":"10","author":"Grenier","year":"2018","journal-title":"Drug Healthc. Patient. Saf."},{"key":"10.1016\/j.ejps.2024.106781_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818777943","article-title":"Proton-pump inhibitors among adults: a nationwide drug-utilization study","volume":"11","author":"H\u00e1lfd\u00e1narson","year":"2018","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"458\u2013464","key":"10.1016\/j.ejps.2024.106781_bib0006","first-page":"e437","article-title":"Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence","volume":"11","author":"Johnson","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2024.106781_bib0007","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(16)32404-7","article-title":"Peptic ulcer disease","volume":"390","author":"Lanas","year":"2017","journal-title":"Lancet"},{"issue":"Suppl 5","key":"10.1016\/j.ejps.2024.106781_bib0008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2036.1999.00034.x","article-title":"Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy","volume":"13","author":"Lew","year":"1999","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106781_bib0009","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10928-005-0074-7","article-title":"How modeling and simulation have enhanced decision making in new drug development","volume":"32","author":"Miller","year":"2005","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2024.106781_bib0010","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/pds.4043","article-title":"Proton pump inhibitor prescribing patterns in the UK: a primary care database study","volume":"25","author":"Othman","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ejps.2024.106781_bib0011","doi-asserted-by":"crossref","first-page":"A17","DOI":"10.1016\/S0016-5085(00)82137-X","article-title":"A PPI is a PPI is a PPI; Lessons from prolonged intragastric pH monitoring","volume":"118","author":"Radu Tutuian","year":"2000","journal-title":"Gastroenterology"},{"year":"2019","author":"report","series-title":"2019 Surveillance of Gastro-Oesophageal Reflux Disease and Dyspepsia in Adults: Investigation and Management (NICE guideline CG184)","key":"10.1016\/j.ejps.2024.106781_bib0012"},{"key":"10.1016\/j.ejps.2024.106781_bib0014","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/j.1875-9114.1997.tb03675.x","article-title":"Proton pump inhibitors and acid-related diseases","volume":"17","author":"Sachs","year":"1997","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.ejps.2024.106781_bib0015","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00228-023-03534-z","article-title":"Proton pump inhibitor use: systematic review of global trends and practices","volume":"79","author":"Shanika","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106781_bib0016","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/ped.13733","article-title":"Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: safety, efficacy, and pharmacokinetics","volume":"61","author":"Shimizu","year":"2019","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.ejps.2024.106781_bib0017","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1046\/j.1365-2036.2001.01108.x","article-title":"Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH","volume":"15","author":"Shirai","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106781_bib0018","article-title":"Mucosal healing effectiveness and safety of anaprazole, a novel PPI, vs. rabeprazole in patients with duodenal ulcers: a randomized double-blinded multicenter phase II clinical trial","volume":"8","author":"Shu","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.ejps.2024.106781_bib0019","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0009-9236(97)90081-3","article-title":"Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4\u2032-hydroxylation phenotype and genotype","volume":"62","author":"Tanaka","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106781_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113146","article-title":"Qualitative and quantitative determination of anaprazole and its major metabolites in human plasma","volume":"183","author":"Tang","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2024.106781_bib0021","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/ajg.2018.29","article-title":"Discontinuing long-term PPI therapy: why, with whom, and how?","volume":"113","author":"Targownik","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejps.2024.106781_bib0022","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/jgh.15119","article-title":"Hospitalizations for peptic ulcer disease in China: current features and outcomes","volume":"35","author":"Zheng","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2024.106781_bib0023","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1097\/CM9.0000000000002508","article-title":"Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study","volume":"135","author":"Zhu","year":"2022","journal-title":"Chin. Med. J. (Engl)"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T22:44:23Z","timestamp":1717022663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724000927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":22,"alternative-id":["S0928098724000927"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106781","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated models of population pharmacokinetics and exposure response to optimize dosage regimen for anaprazole sodium in duodenal ulcer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106781"}}